Navigation Links
Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International
Date:6/26/2011

PHILADELPHIA and LONDON, June 26, 2011 /PRNewswire/ -- The pharmaceutical industry spent less on drug R&D last year than at any time in the last three years, according to data released today from the 2011 Pharmaceutical R&D Factbook complied by CMR International, a Thomson Reuters business.

Key highlights from the 2011 R&D Factbook include:

  • 21 new molecular entities (NMEs) were launched on the global market in 2010, a decrease from 26 in the previous year.
  • 2010 saw the lowest number of NMEs launched by Major Pharma in the past 10 years
  • The number of drugs entering Phase I and Phase II trials fell 47% and 53% respectively
  • Self-originated molecules have a 20% greater chance of reaching the market from Phase III and Submission versus in-licensed or acquired compounds
  • Patient recruitment for clinical trials has shifted towards SE Asia
  • The proportion of total sales from drugs reached an all time high of $856 billion*

The 2011 edition of the Pharmaceutical R&D Factbook shows that R&D expenditure continued to drop in 2010 to an estimated three year low of $68 billion, which is in stark contrast to the growth rate leading up to 2008. The report also highlights that drug success rates continue to show the declining trends of the past decade. There were 55 phase III drug terminations during 2008-2010, more than double the number of terminations during 2005-2007; in addition the number of drugs entering phase III clinical trials fell by 55 percent in 2010.

Faced with more than 110 drugs losing patent exclusivity in the US, including 14 "blockbusters", the world's leading pharmaceutical companies face considerable risk to their revenue streams in next three years. The strategy of in-licensing or acquiring compounds is also facing difficulty, as self-originated drugs currently have a 20% higher chanc
'/>"/>

SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015  Peter Walter was chosen as ... his pioneering work on how proteins are transported between ... regulatory mechanism that cells use to handle stress tied ... a professor of biochemistry at the University of California, ... a range of human diseases related to defective protein ...
(Date:3/27/2015)... York (PRWEB) March 27, 2015 Governor ... 2015 application period for 43North - the world’s largest ... including a grand prize of $1 million, six $500,000 ... from around the world to compete for prizes that ... enterprises in the Western New York region. , ...
(Date:3/26/2015)... The Market Element LLC, a leading ... with Designing Gig LLC to provide website design, development, ... “Forging this alliance with Designing Gig represents a pivotal ... a comprehensive, end-to-end, digital solution for our clients, which ... Chuck Miller, president of The Market Element. “For small ...
(Date:3/26/2015)... 2015 PAREXEL International Corporation (Nasdaq: ... research organization , announced today that the ... acquire all of the business assets of privately-owned ... of specialized pharmacovigilance services, based in Chandigarh, ... assessment, monitoring, and prevention of adverse effects ...
Breaking Biology Technology:German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 2German-born cell biologist Peter Walter wins the 2015 Vilcek Prize in Biomedical Science 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... 2012  AnaptysBio, Inc., a privately-held therapeutic antibody ... strategic alliances with two partners: Novartis and ... alliance announced today with Novartis is AnaptysBio,s ... and follows an initial partnership where AnaptysBio ...
... in the human body is moved by its strongest muscles: ... enormous strengths are working on the surface of our teeth. ... for dentures, inlays or bridges", glass chemist Prof. Dr. Dr. ... After all, these are worn as much as healthy teeth. ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today ... update on the progress of Sangamo,s ZFP Therapeutic® development programs ... am PT (10:30 am ET) on Thursday, January 12, 2012, ... be held in San Francisco. The presentation will ...
Cached Biology Technology:AnaptysBio Announces New Strategic Antibody Discovery 2AnaptysBio Announces New Strategic Antibody Discovery 3Nanocrystals make dentures shine 2Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference 2
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and Markets ... "Face and Voice Biometrics - Global Strategic Business Report" report ... for Face and Voice Biometrics in US$ Thousands by the following ... analytics for the US, Canada , ... , Middle East & ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... the University of California, San Diego, have found that ... patterns of fur coloration that camouflage mice against their ... this week in the journal PLoS Biology, marks one ... have been linked to an organism,s ability to survive ...
... Researchers at Rensselaer Polytechnic Institute have developed a new ... a simple sheet of black paper. The nanoengineered ... toward meeting the trickiest design and energy requirements of ... Along with its ability to function in temperatures up ...
... Not all patients with sepsis mount the same immune ... to findings from the first large-scale natural history study ... School of Medicine researchers in the August 13/27 issue ... interpretations of how the immune system responds to infection ...
Cached Biology News:Interaction of just 2 genes governs coloration patterns in mice 2Beyond batteries: Storing power in a sheet of paper 2Beyond batteries: Storing power in a sheet of paper 3Study begins to reveal clues to the cause and progression of sepsis 2Study begins to reveal clues to the cause and progression of sepsis 3
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
Luminometers...
cDNA Size Fractionation Columns offer an efficient and convenient method for size-fractioning double-stranded cDNA....
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Biology Products: